Comparator: vorinostat
Pre-clinicalCompleted 1 views this week 0 watching💤 Quiet
Interest: 26/100
26
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Lymphoma, T-Cell, Cutaneous
Conditions
Lymphoma, T-Cell, Cutaneous
Trial Timeline
— → —
NCT ID
NCT00419367About Comparator: vorinostat
Comparator: vorinostat is a pre-clinical stage product being developed by Merck for Lymphoma, T-Cell, Cutaneous. The current trial status is completed. This product is registered under clinical trial identifier NCT00419367. Target conditions include Lymphoma, T-Cell, Cutaneous.
What happened to similar drugs?
18 of 20 similar drugs in Lymphoma, T-Cell, Cutaneous were approved
Approved (18) Terminated (0) Active (2)
Hype Score Breakdown
Clinical
3
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00419367 | Pre-clinical | Completed |
Competing Products
20 competing products in Lymphoma, T-Cell, Cutaneous